[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1259142A1 - Egfr抑制劑游離碱或其酸式鹽的多晶型、其製備方法和應用 - Google Patents

Egfr抑制劑游離碱或其酸式鹽的多晶型、其製備方法和應用

Info

Publication number
HK1259142A1
HK1259142A1 HK19101108.6A HK19101108A HK1259142A1 HK 1259142 A1 HK1259142 A1 HK 1259142A1 HK 19101108 A HK19101108 A HK 19101108A HK 1259142 A1 HK1259142 A1 HK 1259142A1
Authority
HK
Hong Kong
Prior art keywords
preparation
application
acid salt
free base
method therefor
Prior art date
Application number
HK19101108.6A
Other languages
English (en)
Inventor
陳中科
劉福萍
劉磊
包如迪
Original Assignee
江蘇豪森藥業集團有限公司
上海翰森生物醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇豪森藥業集團有限公司, 上海翰森生物醫藥科技有限公司 filed Critical 江蘇豪森藥業集團有限公司
Publication of HK1259142A1 publication Critical patent/HK1259142A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK19101108.6A 2016-03-22 2019-01-22 Egfr抑制劑游離碱或其酸式鹽的多晶型、其製備方法和應用 HK1259142A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610165018 2016-03-22
PCT/CN2016/111717 WO2017161937A1 (zh) 2016-03-22 2016-12-23 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用

Publications (1)

Publication Number Publication Date
HK1259142A1 true HK1259142A1 (zh) 2019-11-29

Family

ID=59899195

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101108.6A HK1259142A1 (zh) 2016-03-22 2019-01-22 Egfr抑制劑游離碱或其酸式鹽的多晶型、其製備方法和應用

Country Status (12)

Country Link
US (3) US10759782B2 (zh)
EP (1) EP3434673B1 (zh)
JP (1) JP7007287B2 (zh)
KR (1) KR20180131572A (zh)
CN (3) CN112645933B (zh)
AU (1) AU2016399168B2 (zh)
CA (1) CA3016092A1 (zh)
ES (1) ES2857805T3 (zh)
HK (1) HK1259142A1 (zh)
RU (1) RU2733412C2 (zh)
TW (1) TWI736570B (zh)
WO (1) WO2017161937A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112645933B (zh) * 2016-03-22 2022-02-11 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用
CN110317265B (zh) * 2018-03-28 2023-03-10 江苏豪森药业集团有限公司 比伐芦定晶型a及其制备方法
CN110719782B (zh) * 2018-05-15 2023-02-07 江苏豪森药业集团有限公司 包含第三代小分子egfr抑制剂的药物组合物及其制备方法
CN111818925B (zh) * 2018-05-23 2023-12-12 江苏恒瑞医药股份有限公司 Cdk4/6抑制剂与egfr抑制剂联合在制备治疗肿瘤疾病的药物中的用途
CN110652514A (zh) * 2018-06-29 2020-01-07 上海翰森生物医药科技有限公司 第三代egfr抑制剂的制药用途
TW202100150A (zh) * 2019-03-04 2021-01-01 大陸商江蘇恒瑞醫藥股份有限公司 多靶點酪胺酸激酶抑制劑與egfr抑制劑聯合在製備治療腫瘤的藥物中的用途
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
CN113179640B (zh) * 2019-11-26 2024-06-25 上海翰森生物医药科技有限公司 含氮多环类衍生物抑制剂、其制备方法和应用
CN113679723B (zh) * 2020-05-19 2024-11-05 蚌埠医学院 Egfr抑制剂制备治疗乳腺癌药物的用途
TW202222795A (zh) * 2020-11-19 2022-06-16 大陸商上海翰森生物醫藥科技有限公司 一種含吲哚類衍生物的鹽、晶型及其製備方法和應用
CN112457299B (zh) * 2020-12-14 2021-12-17 江苏豪森药业集团有限公司 Egfr抑制剂的纯化方法
EP4324829A1 (en) * 2021-04-12 2024-02-21 MitoImmune Therapeutics Inc. Sulfate of 5-[(1,1-dioxido-4-thiomorpholinyl)methyl]-2-phenyl-n-(tetrahydro-2h-pyran-4-yl)-1h-indole-7-amine, and novel crystal form thereof
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4337341A (en) * 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
RS62542B1 (sr) * 2011-07-27 2021-12-31 Astrazeneca Ab 2-(2,4,5-supstituisani-anilino) pirimidinski derivati
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
CN103819461B (zh) * 2012-11-19 2016-06-15 齐鲁制药有限公司 N-[3-氯-4-(3-氟苄氧基)苯基]-6-[5-[[2-(甲亚磺酰基)乙基]氨基]甲基]-2-呋喃基]-4-喹唑啉胺多晶型物及其制备方法
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
JP6230205B2 (ja) * 2014-06-19 2017-11-15 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
CN104140418B (zh) * 2014-08-15 2016-08-24 常州润诺生物科技有限公司 2-(2，4，5-取代苯胺)嘧啶衍生物及其用途
PL3205650T3 (pl) * 2014-10-11 2021-12-06 Shanghai Hansoh Biomedical Co., Ltd. Inhibitor EGFR i jego otrzymywanie i zastosowanie
CN104961731A (zh) * 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN112645933B (zh) * 2016-03-22 2022-02-11 江苏豪森药业集团有限公司 Egfr抑制剂游离碱或其酸式盐的多晶型、其制备方法和应用

Also Published As

Publication number Publication date
EP3434673A1 (en) 2019-01-30
US20200361909A1 (en) 2020-11-19
TW201734006A (zh) 2017-10-01
KR20180131572A (ko) 2018-12-10
RU2733412C2 (ru) 2020-10-01
JP7007287B2 (ja) 2022-01-24
CN112645932B (zh) 2022-01-14
EP3434673B1 (en) 2021-02-17
CA3016092A1 (en) 2017-09-28
WO2017161937A1 (zh) 2017-09-28
CN108884072A (zh) 2018-11-23
RU2018135643A3 (zh) 2020-04-22
TWI736570B (zh) 2021-08-21
CN112645933A (zh) 2021-04-13
AU2016399168A1 (en) 2018-10-25
US20220281847A1 (en) 2022-09-08
CN108884072B (zh) 2020-12-22
CN112645933B (zh) 2022-02-11
JP2019509290A (ja) 2019-04-04
US10759782B2 (en) 2020-09-01
CN112645932A (zh) 2021-04-13
RU2018135643A (ru) 2020-04-22
US20190077791A1 (en) 2019-03-14
US11155534B2 (en) 2021-10-26
ES2857805T3 (es) 2021-09-29
AU2016399168B2 (en) 2021-01-21
EP3434673A4 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
HK1259142A1 (zh) Egfr抑制劑游離碱或其酸式鹽的多晶型、其製備方法和應用
ZA201701465B (en) Egfr inhibitor, and preparation and application thereof
HK1254666A1 (zh) 一種egfr抑制劑的鹽、晶型及其用途
EP3317273A4 (en) EGFR HEMMER AND METHOD OF USE THEREOF
HUE049952T2 (hu) Pirazolon vegyület vagy sója, elõállítási eljárása, herbicid hatású készítménye és alkalmazása
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
EP3369734A4 (en) KINASEINHIBITOR AND METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF
HUE059672T2 (hu) Kinolinvegyületek, eljárás azok elõállítására, és urát transzporter inhibitor gyógyzserként történõ alkalmazásuk
HK1219952A1 (zh) 激酶抑制劑及其製備方法和應用
EP3327014A4 (en) Egfr inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
HK1244278B (zh) 喹唑啉衍生物的鹽及其製備方法
SG11202007554TA (en) Dioxazoline compound, preparation method therefor, and uses thereof
ZA201802141B (en) Egfr kinase inhibitor and preparation method and use thereof
EP3298151A4 (en) METHOD AND COMPOSITIONS FOR DETERMINING THE PH VALUE
EP3235851A4 (en) Nylon salt and preparation method therefor
EP3299395A4 (en) OXIDIZED 1,4-OLIGOGLUCURONIC ACID, MANUFACTURING METHOD AND USES THEREOF
EP3562830C0 (en) HYDROXYBENZOIC ACID DERIVATIVES, METHODS AND USES THEREOF
HK1246279A1 (zh) C14-位羥基酯化的雷公藤甲素氨基酸衍生物、及其製備方法和應用
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
PL3330267T3 (pl) Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
PT3722282T (pt) Forma de sal e forma cristalina que servem como compostos inibidores de fgfr e vegfr, e método de preparação para esse fim
ZA201800493B (en) Deuterated thienopiperidine derivatives, manufacturing method, and application thereof
EP3521815A4 (en) METHOD OF MEASURING PH
EP3269710A4 (en) Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
ZA201903845B (en) Fgfr4 inhibitor and preparation method and use thereof